# A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease

> **NCT05890001** · PHASE3 · COMPLETED · sponsor: **Braintree Laboratories** · enrollment: 400 (actual)

## Conditions studied

- Non-erosive Reflux Disease
- Erosive Esophagitis

## Interventions

- **DRUG:** BLI5100

## Key facts

- **NCT ID:** NCT05890001
- **Lead sponsor:** Braintree Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-05
- **Primary completion:** 2024-10-08
- **Final completion:** 2024-10-08
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2025-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05890001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05890001, "A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05890001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*